Acute kidney injury during Vancomycin Therapy in critically ill children

Pharmacotherapy

Volumn 33, Issue 6, 2013, Pages 598-602

  Totapally, Balagangadhar R ^a,b   Machado, Jacqueline ^c,d   Lee, Helen ^a   Paredes, Ana ^a   Raszynski, Andre ^a,b  

^a MIAMI CHILDREN'S HOSPITAL   (United States)

^b FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^c Chris Evert Children's Hospital   (United States)

^d Coral Springs Medical Center ^*  (United States)

Author keywords

Acute kidney injury; Child; Critical care; Renal failure; Vancomycin

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; CARBOPLATIN; CISPLATIN; CREATININE; CYCLOSPORIN; GANCICLOVIR; GENTAMICIN; IFOSFAMIDE; KETOROLAC; METHOTREXATE; NITROGEN; PENTAMIDINE; TACROLIMUS; TOBRAMYCIN; UREA; VANCOMYCIN;

ACUTE KIDNEY FAILURE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INFANT; INTENSIVE CARE UNIT; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORBIDITY; NEPHROTOXICITY; OUTCOME ASSESSMENT; PATIENT MONITORING; PEDIATRIC HOSPITAL; PRESCHOOL CHILD; RETROSPECTIVE STUDY; RISK FACTOR; SCHOOL CHILD; SIDE EFFECT; TERTIARY HEALTH CARE; TREATMENT DURATION; UREA NITROGEN BLOOD LEVEL;

ACUTE KIDNEY INJURY; ADOLESCENT; ANALYSIS OF VARIANCE; ANTI-BACTERIAL AGENTS; BLOOD UREA NITROGEN; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CRITICAL ILLNESS; FEMALE; GLOMERULAR FILTRATION RATE; HOSPITALS, PEDIATRIC; HUMANS; INFANT; INTENSIVE CARE UNITS, PEDIATRIC; LOGISTIC MODELS; MALE; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; VANCOMYCIN;

EID: 84879585901     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1259     Document Type: Article

References (36)

1. Glover ML, Cole E, Wolfsdorf J. Vancomycin dosage requirements among pediatric intensive care unit patients with normal renal function. J Crit Care 2000;15(1):1-4.
2. Grohskopf LA, Huskins WC, Sinkowitz-Cochran RL, et al. Use of antimicrobial agents in United States neonatal and pediatric intensive care patients. Pediatr Infect Dis J 2005;24 (9):766-773.
3. Hazlewood KA, Brouse SD, Pitcher WD, Hall RG. Vancomycin- associated nephrotoxicity: grave concern or death by character assassination? Am J Med 2010;123(2):182 e1-e7.
4. Wu CY, Wang JS, Chiou YH, Chen CY, Su YT. Biopsy proven acute tubular necrosis associated with vancomycin in a child: case report and literature review. Ren Fail 2007;29(8):1059-1061.
5. Oktem F, Arslan MK, Ozguner F, et al. In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin- induced nephrotoxicity: protection by erdosteine. Toxicology 2005;215(3):227-233.
6. Nishino Y, Takemura S, Minamiyama Y, et al. Targeting superoxide dismutase to renal proximal tubule cells attenuates vancomycin-induced nephrotoxicity in rats. Free Radic Res 2003;37(4):373-379.
7. Nishino Y, Takemura S, Minamiyama Y, et al. Inhibition of vancomycin-induced nephrotoxicity by targeting superoxide dismutase to renal proximal tubule cells in the rat. Redox Rep 2002;7(5):317-319.
8. Ingram PR, Lye DC, Tambyah PA, Goh WP, Tam VH, Fisher DA. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. J Antimicrob Chemother 2008;62(1):168-171.
9. Elting LS, Rubenstein EB, Kurtin D, et al. Mississippi mud in the 1990s: risks and outcomes of vancomycin-associated toxicity in general oncology practice. Cancer 1998;83(12):2597-2607.
10. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006;166(19):2138-2144.
11. Goetz MB, Sayers J. Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination. J Antimicrob Chemother 1993;32(2):325-334.
12. Farber BF, Moellering RC Jr. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother 1983;23(1):138-141.
13. Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008;52(4):1330-1336.
14. McKamy S, Andez E, Jahng M, Moriwaki T, Deveikis A, Le J. Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children. J Pediatr 2011;158 (3):422-426.
15. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentrationtime profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009;49(4):507-514.
16. Pritchard L, Baker C, Leggett J, Sehdev P, Brown A, Bayley KB. Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity. Am J Med 2010;123(12):1143-1149.
17. Hermsen ED, Hanson M, Sankaranarayanan J, Stoner JA, Florescu MC, Rupp ME. Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections. Expert Opin Drug Saf 2010;9(1):9-14.
18. Fisher BT, Zaoutis TE, Leckerman KH, Localio R, Aplenc R. Risk factors for renal failure in pediatric patients with acute myeloid leukemia: a retrospective cohort study. Pediatr Blood Cancer 2010;55(4):655-661.
19. Bhatt-Mehta V, Schumacher RE, Faix RG, Leady M, Brenner T. Lack of vancomycin-associated nephrotoxicity in newborn infants: a case-control study. Pediatrics 1999;103(4):e4e8.
20. Akcan-Arikan A, Zappitelli M, Loftis LL, Washburn KK, Jefferson LS, Goldstein SL. Modified RIFLE criteria in critically ill children with acute kidney injury. Kidney Int 2007;71 (10):1028-1035.
21. Plotz FB, Bouma AB, Van Wijk JA, Kneyber MC, Bökenkamp A. Pediatric acute kidney injury in the ICU: an independent evaluation of pRIFLE criteria. Intensive Care Med 2008;34 (9):1713-1717.
22. Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 1987;34(3):571-590.
23. Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976;58(2):259-263.
24. King DW, Smith MA. Proliferative responses observed following vancomycin treatment in renal proximal tubule epithelial cells. Toxicol In Vitro 2004;18(6):797-803.
25. Celik I, Cihangiroglu M, Ilhan N, Akpolat N, Akbulut HH. Protective effects of different antioxidants and amrinone on vancomycin-induced nephrotoxicity. Basic Clin Pharmacol Toxicol 2005;97(5):325-332.
26. Zimmermann AE, Katona BG, Plaisance KI. Association of vancomycin serum concentrations with outcomes in patients with gram-positive bacteremia. Pharmacotherapy 1995;15 (1):85-91.
27. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009;66(1):82-98.
28. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital- acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171(4):388-416.
29. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005;111(23):e394-e434.
30. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011;52(3):e18-e55.
31. Barrantes F, Tian J, Vazquez R, Amoateng-Adjepong Y, Manthous CA. Acute kidney injury criteria predict outcomes of critically ill patients. Crit Care Med 2008;36(5):1397-1403.
32. Aronoff GR, Sloan RS, Dinwiddie CB Jr, Glant MD, Fineberg NS, Luft FC. Effects of vancomycin on renal function in rats. Antimicrob Agents Chemother 1981;19(2):306-308.
33. Wold JS, Turnipseed SA. Toxicology of vancomycin in laboratory animals. Rev Infect Dis 1981;3(suppl):S224-S229.
34. Beauchamp D, Pellerin M, Gourde P, Pettigrew M, Bergeron MG. Effects of daptomycin and vancomycin on tobramycin nephrotoxicity in rats. Antimicrob Agents Chemother 1990;34 (1):139-147.
35. Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef MH. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillinresistant Staphylococcus aureus pneumonia. Clin Ther 2007;29 (6):1107-1115.
36. Darko W, Medicis JJ, Smith A, Guharoy R, Lehmann DE. Mississippi mud no more: cost-effectiveness of pharmacokinetic dosage adjustment of vancomycin to prevent nephrotoxicity. Pharmacotherapy 2003;23(5):643-650.